Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study aimed to identify characteristics of patients who fail to void during pressure-flow studies, which limits the determination of the cause behind their lower urinary tract symptoms.

Human prostate cells produce more WISP1/CCN4 when there's not enough oxygen.

This article from BJU International discusses the slow progress in prostate cancer research and reports no new findings.

This study observed no association between androgenetic alopecia and benign prostatic hyperplasia in men aged 20 and older, although a positive family history was linked to early onset of hair loss.

This study found that patients with androgenetic alopecia frequently had higher PSA levels and more significant urinary symptoms, likely due to older age, though prostate weight did not differ.

This study found that men with early-onset androgenetic alopecia had larger prostate volumes and lower urinary flow rates compared to those without the condition, suggesting a potential link between AGA and urinary symptoms.

In this study, patients informed about finasteride's potential sexual side effects reported a significantly higher occurrence of these side effects, suggesting a nocebo effect.

In this study, the researchers did not confirm previously reported links between AGA and smoking or benign prostatic hypertrophy, but found potential associations with alcohol consumption and lean body mass at age 21 that merit further investigation.

This review discusses the extraction, purification, modification, and biological activity of polysaccharides from Traditional Chinese Medicine and reports no new research findings.

This review discusses current and emerging treatments for benign prostatic hyperplasia and emphasizes the need for further research to optimize treatment selection, but reports no new clinical results.

This review discusses phytotherapy options for managing benign prostatic hyperplasia, noting some herbal agents show promise in trials for mild-moderate symptoms but more evidence is needed for others.

This study found that 5α-reductase inhibitors significantly increase the risk of erectile dysfunction and hypoactive sexual desire in men with benign prostatic hyperplasia, compared to placebo.

This study found that finasteride significantly reduced symptom severity scores in patients with inflammatory chronic pelvic pain syndrome, though its effect on pain was not significant.

This study found low- to very low-quality evidence suggesting that several pharmacological treatments, including alpha blockers and antibiotics, may reduce prostatitis symptoms without significantly increasing adverse events in the short term, although more rigorous trials are needed.

This study found that dutasteride effectively improved urinary symptoms, reduced acute urinary retention risk, and decreased prostate volume in men with moderate to severe BPH over two years.

This study found that 5‐α‐reductase inhibitors reduce the risk of being diagnosed with prostate cancer in men who undergo regular screening, but increase the risk of sexual and erectile dysfunction.

This study concluded that finasteride is a viable first-line treatment for moderate uncomplicated benign prostatic hyperplasia, particularly in patients with larger prostates, by significantly reducing acute urinary retention and the need for surgery.

This study concluded that five-alpha-reductase inhibitors may reduce prostate cancer risk but could increase the risk of high-grade prostate cancer in men regularly screened for the disease.

This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.

This study suggests that a larger prostate is associated with a higher prevalence of androgenetic alopecia, although the prostate size did not correlate with alopecia severity.

This study found that men aged 50 and older with clinical benign prostatic hyperplasia have a significantly higher prevalence of metabolic syndrome than those without the condition in the UK primary care population.

Combination therapy improves urinary flow and reduces residual urine, but needs better stent design.

This study found that finasteride improved urodynamic measures of obstruction in men with benign prostatic enlargement and lower urinary tract symptoms, with continued improvement over two years of treatment.

This study found that testosterone treatment in older hypogonadal men caused minor improvements in depressive symptoms and visuospatial memory, but overall, major cognitive benefits were not observed.

This review discusses recent advancements and new approvals in the medical treatment of lower urinary tract symptoms, particularly highlighting drugs for nocturia and ongoing trials for multiple related conditions, while reporting no new clinical results.

This study found that long-term finasteride therapy in men with BPH worsened erectile dysfunction and reduced testosterone levels, while these effects were not observed with tamsulosin.

This study reports that newly synthesized steroidal trienones exhibit higher 5α-reductase inhibitory activity than dienones in various biological models, suggesting potential use in treating androgen-dependent diseases.

In this study, the researchers found that worse sleep scores were associated with progression of lower urinary tract symptoms and suggestively linked to their development in asymptomatic men.

This study found that patients with bladder outlet obstruction and moderately enlarged prostates are likely to successfully discontinue the a-blocker doxazosin after 9 months of combination therapy with finasteride.

This review discusses sexual dysfunction as a side effect of α-blockers and 5-ARIs for BPH/LUTS, highlighting methodological flaws in existing studies and the need for more rigorous research.